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ABSTRACT  
Prediction models for colorectal cancer (CRC) detection in symptomatic 
patients, based on easily obtainable variables such as faecal haemoglobin 
concentration (f-Hb), age and sex, may simplify CRC diagnosis. We developed, 
and then externally validated, a multivariable prediction model, the FAST Score, 
with data from five diagnostic test accuracy studies that evaluated quantitative 
faecal immunochemical tests in symptomatic patients referred for colonoscopy. 
The diagnostic accuracy of the Score in derivation and validation cohorts was 
compared statistically with the area under the curve (AUC) and the Chi-square 
test.1,572 and 3,976 patients were examined in these cohorts, respectively. For 
CRC, the odds ratio (OR) of the variables included in the Score were: age 
(years): 1.03 (95% confidence intervals (CI): 1.02-1.05), male sex: 1.6 (95% CI: 
1.1-2.3) and f-Hb (0-<20 µg Hb/g faeces): 2.0 (95% CI: 0.7-5.5), (20-<200 µg 
Hb/g): 16.8 (95% CI: 6.6-42.0), ≥200 µg Hb/g:  65.7 (95% CI: 26.3-164.1). The 
AUC for CRC detection was 0.88 (95% CI: 0.85-0.90) in the derivation and 0.91 
(95% CI: 0.90-093; p = 0.005) in the validation cohort. At the two Score 
thresholds with 90% (4.50) and 99% (2.12) sensitivity for CRC, the Score had 
equivalent sensitivity, although the specificity was higher in the validation cohort 
(p<0.001). Accordingly, the validation cohort was divided into three groups: high 
(21.4% of the cohort, positive predictive value - PPV: 21.7%), intermediate 
(59.8%, PPV: 0.9%) and low (18.8%, PPV: 0.0%) risk for CRC. The FAST 
Score is an easy to calculate prediction tool, highly accurate for CRC detection 
in symptomatic patients. 
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Novelty and Impact 
Lower gastrointestinal symptoms are very common in patients presenting in 
primary care, but colorectal cancer (CRC) is much rarer. Faecal haemoglobin 
concentration (f-Hb), at low thresholds, is a good rule-in test for CRC, but is 
dependent on age and sex. The FAST Score, based on the easily available 
variables of f-Hb, age and sex, has high diagnostic accuracy for CRC detection 
in symptomatic patients. It can be applied to generate three easy to interpret 
categories of risk to simplify referrals for colonoscopy.   
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INTRODUCTION 
 
Colorectal cancer (CRC) remains an important health problem in 
Western Europe. It is the seventh cause of death and the fourth cause of years 
of life lost.1  Health authorities have developed two main strategies to reduce 
the impact of CRC: screening in average and, on occasion, high-risk (personal 
or family history of CRC or adenomas) populations, and prompt detection in 
symptomatic patients.2–6  
Although screening programmes are being progressively implemented, 
most CRC are detected when symptoms become apparent.7 In addition, 
although gastrointestinal symptoms are extremely common in the population, 
the probability of CRC detection associated with any one symptom is low.8–10 
Which symptomatic patients should be evaluated promptly, mainly with 
colonoscopy, is the dilemma in any diagnostic strategy. Over-investigation 
generates financial costs and patients are subjected to psychological impact 
and unnecessary endoscopy-related risk and discomfort. On the other hand, 
lack of investigation risks a delay in diagnosis with clinical and possibly 
medicolegal impact.   
In order to reach a balance, several approaches that use criteria for 
referral for colonoscopy that are associated with a high risk for CRC have been 
established. In this regard, the best known guidelines are the very detailed and 
extremely prescriptive National Institute for Health and Care Excellence (NICE) 
criteria for suspected cancer.3,11 Additionally, a number of CRC prediction 
models have been designed and validated in different settings. These prediction 
models, systematically reviewed in detail recently, are calculated from 
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mathematical equations based mainly on symptoms, although information 
regarding demographics, other variables and results of investigations are 
sometimes also included.12  Although their diagnostic accuracy  is generally 
deemed to be satisfactory and better than the existing referral criteria, these 
prediction models have not been widely implemented, in part due to their 
complexity and the difficulty of collection of all of the spectrum of variables 
required.13–15  
 Faecal immunochemical tests for haemoglobin (FIT) have proven to be 
the best currently available non-invasive test for CRC screening in 
asymptomatic individuals and an excellent test for rule-in of CRC and rule-out of 
significant colonic lesions (SCL) in patients presenting with lower 
gastrointestinal symptoms.16–21 Quantitative FIT allow for assessment of faecal 
hemoglobin concentration (f-Hb). There are several prediction models in 
asymptomatic individuals for CRC screening based on f-Hb,22 and a CRC 
prediction model in symptomatic patients including f-Hb has been recently 
developed and externally validated.23 This prediction model was shown to have 
high diagnostic accuracy and discriminated between three risk groups, one of 
them with a negligible risk for CRC.  However, its applicability may be limited 
due to its complexity, since the model includes eleven variables.   
In consequence, we carried out a derivation and external validation 
multivariable prediction  model study, based on the hypothesis that a simple to 
calculate risk score, based on only three readily available variables - f-Hb, age 
and sex - could simplify the evaluation of symptomatic patients and provide a 
easy to use tool for the risk stratification of these to facilitate prioritisation of 
referrals for endoscopy.20 In order to perform this study on the FAST Score, 
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detailed data obtained in five previously peer-reviewed and published studies 
evaluating the diagnostic accuracy of FIT in 5,548 symptomatic patients 
referred for colonoscopy were used.16–21,23  
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PATIENTS AND METHODS 
 
1. Design  
The development and external validation of the multivariable prediction 
model was designed according to the TRIPOD guidelines.24  All diagnostic 
accuracy studies from which data were derived for this work were performed 
according to the STARD guidelines,25 as documented in the relevant 
publications.16–21,23 
 
2. Derivation cohort 
The derivation cohort consisted of 1,572 consecutive symptomatic 
patients referred to colonoscopy in Ourense, Spain, between March 2012 and 
September 2013, who were included in the derivation cohort of the 
COLONPREDICT study.23 The exclusion criteria have been detailed 
elsewhere.23 
All patients collected one faecal sample from a single bowel movement 
during the week before the colonoscopy. They were specifically instructed to 
sample the passed faeces where no blood was visible. f-Hb was determined 
using the automated OC-SENSOR MICRO analyser (Eiken Chemical Co., Ltd, 
Tokyo, Japan). Colonoscopy was performed blind to the analytical results. The 
characteristics of this derivation cohort and the main endoscopic findings are 
shown in Table 1. 
 
3. Validation cohort: 
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The validation  cohort included 3,976 symptomatic patients recruited in 
five studies evaluating the diagnostic accuracy of different FIT analytical 
systems for CRC, advanced neoplasia (AN), and significant colonic lesion 
(SCL) detection or exclusion in symptomatic patients.17,19–21,23 The 
characteristics of the different cohorts with respect to age, sex, colonoscopy 
findings, reasons for primary care referral and FIT system used are shown in 
Table 1. The particulars of these five studies are documented in detail in the 
relevant publications. 17-21 
All studies were approved by the local Clinical Research Ethics 
Committees and patients provided written informed consent in the Spanish 
studies. In the three Scottish studies, Research Ethics Committees stated that, 
if the patient returned a sample for f-Hb measurement, consent was implied.   
Estimates of f-Hb were quantitated as µg Hb/g faeces so that results could be 
compared across analytical systems.26 
 
4. Main outcome: 
The main outcome of this study was CRC detection. The secondary 
outcomes were advanced neoplasia (AN) and significant colonic lesions (SCL) 
diagnosis. AN was defined in the Spanish studies as advanced adenomas (≥10 
mm, villous histology, high-grade dysplasia) or CRC and, in the studies done in 
Scotland, more simply as higher-risk adenoma (>10 mm, or more than three) or 
CRC. SCL was defined in Spain as any of the following: CRC, AN, polyposis 
(>10 polyps of any histology, including serrated lesions), colitis (any aetiology), 
polyps ≥10 mm (including serrated lesions), complicated diverticular disease 
(diverticulitis, bleeding), colonic ulcer or bleeding angiodysplasia, In Scotland, 
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again more simply, SCL was defined as any of CRC, AN or inflammatory bowel 
disease (IBD – Crohn’s or ulcerative colitis); other lesions (non-advanced 
adenomas, non-complicated diverticular disease, polyps <10mm, non-bleeding 
angiodysplasia, haemorrhoids) were considered non-significant colonic lesions.  
 
 
5. Development of the prediction tool 
Three variables were included in the FAST Score prediction tool:  the 
acronym is based on the Faecal haemoglobin concentration, Age and Sex Test 
Score. Before logistic regression, we performed a univariate analysis using 
Generalised Additive Model models with smoothing splines for continuous 
variables. The objective of this analysis was to determine, in those nonlinear 
variables, the different strata or classes. Age was introduced as a continuous 
variable. In contrast, f-Hb had to be introduced as a categorical variable since it 
is not appropriate for introduction as a continuous variable in a logistic 
regression model. This is because f-Hb did not have a normal distribution, even 
after logarithmic transformation; in addition, the risk of CRC did not have a 
linear relationship to f-Hb in spite of f-Hb being related to colonic disease 
severity. On account of previous findings,16–21 we decided to use three 
thresholds in f-Hb concentration: 0 µg Hb/g faeces (with the theoretical potential 
to rule out CRC and SCL),19,21 20 µg Hb/g faeces (the threshold used in many 
CRC screening programmes) and, finally, 200 µg Hb/g faeces, the upper limit of 
the analytical working range of the most commonly used FIT analytical system, 
the OC-Sensor. (Eiken) In consequence four categories were defined: (1)  0 µg 
Hb/g faeces, (2) between 0 and below 20 µg Hb/g faeces, (3) between 20 and 
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below 200 µg Hb/g faeces and (4) more than 200 µg Hb/g faeces. The 
regression coefficients were used to construct a CRC prediction Score, where 
the dependent variable was the presence or absence of CRC. We calculated 
the area under the curve (AUC) from the receiver operating characteristic 
(ROC) curve analyses. The calibration of the model in the derivation cohort was 
evaluated with the Hosmer-Lemeshow test 
In order to evaluate the diagnostic yield of the final prediction tool, two 
threshold Scores were established with 90% and 99% sensitivity for CRC 
detection, and the diagnostic accuracy for CRC, AN and SCL were determined 
at each of these thresholds. Using these threshold Scores, the cohorts were 
dissected into three groups: high, intermediate and low risk for CRC detection. 
The number of patients, the positive predictive value (PPV) and the number 
needed to scope (NNS) to detect one CRC, AN, or SCL were calculated for 
each group. Finally, we expressed the differences in risk as Odds Ratios (OR) 
with 95% confidence intervals (CI).  
 
6. External validation: 
  We used the coefficients to calculate the FAST score for each patient in 
the validation dataset. Those patients that met the criteria for 90% and 99% 
sensitivity were determined. The diagnostic accuracy of the model in the 
derivation and the validation cohorts were compared with, firstly, with the AUC 
derived from ROC curves  and, secondly,  with the Chi-square test to determine 
differences in sensitivity and specificity at the two threshold Scores between the 
cohorts for CRC, AN and SCL detection. The calibration of the model in the 
validation cohort was evaluated with the Hosmer-Lemeshow test. 
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7. Diagnostic accuracy according to additional variables: 
Finally, a post-hoc analysis of the model was performed in the validation 
cohort to determine if its diagnostic accuracy  for CRC detection was altered on 
the basis of the level of healthcare at which the patient was referred for 
colonoscopy (primary or secondary), the country in which the study was 
performed (Spain or Scotland), the CRC prevalence (<5% or >5%) in the study 
group, sex (male or female), age (<50 or ≥50 years), the individual study and, 
finally, the particular FIT analytical system used to estimate f-Hb.  In order to 
perform this analysis, diagnostic accuracy was compared with AUC derived 
from ROC curves and sensitivity and specificity with the Chi-square test. 
Data are reported with 95% CI. A p-value <0.05 was considered to be 
statistically significant. Analysis was carried out using SPSS statistical software, 
version 15.0 (SPSS Inc., Chicago, IL) and EPIDAT 3.1 (Dirección Xeral de 
Saúde Pública, Santiago de Compostela, Spain). 
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RESULTS 
 
1. Development of the Score prediction model 
The odds ratio (OR) of the variables included in the model were: age 
(years): 1.03, 95% (CI 1.02-1.05), male sex: 1.6 (95% CI: 1.1-2.3) and f-Hb (0-
<20 µg Hb/g faeces): 2.0 (95% CI: 0.7-5.5), (20-<200 µg Hb/g): 16.8 (95% CI: 
6.6-42.0), ≥200 µg Hb/g: 65.7 (95% CI: 26.3-164.1). The mathematical formula 
to calculate the FAST Score (b coefficient) is as follows:   0.684 x f-Hb (0, 20) 
µg Hb/g faeces + 2.824 x f-Hb [20, 200) µg Hb/g faeces + 4.184 x f-Hb ≥200 µg 
Hb/g faeces + 0.031 x age (years) + 0.479 x sex (male). The intercept term of 
the equation is -6.689. The FAST Score had an AUC for CRC diagnosis in the 
ROC analysis of 0.88 (95% CI: 0.85-0.90).   The Hosmer Lemeshow test 
significance was p=0.4. 
 
2. Diagnostic accuracy of the Score in the derivation cohort 
The thresholds for the b-coefficient of the FAST Score with 90 and 99% 
sensitivity were 4.50 and 2.12, respectively. The b-coefficient was at least 4.50 
in 37.1% and 2.12 in 88.0% of the patients included in the derivation cohort. 
Data on the diagnostic accuracy of the Score for CRC detection using these two 
threshold Scores are shown in Table 2. The overall AUC for AN detection was 
0.82 (95% CI: 0.80-0.84) and for SCL was 0.82 (0.79-0.84). At the threshold 
Score of 4.50, the tool had a sensitivity for AN and SCL detection of 75.4% 
(95% CI: 70.9-79.4) and 72.7% (95% CI: 68.4-76.7), respectively. Moreover, at 
the threshold Score of 2.12, the sensitivity rose to 98.8% (95% CI: 97.1-99.6) 
and 97.8% (95% CI 95.9-98.9) for AN and SCL, respectively. 
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According to these two threshold Scores, the derivation cohort was 
dissected into three risk groups: high (Score ≥4.50), intermediate (Score <4.50 
and ≥2.12) and low (Score <2.12). The diagnostic yields of this classification for 
CRC, AN and SCL detection are shown in Table 3. In summary, while the NNS 
to detect a CRC, or an AN, or a SCL were 35.7, 8.1, and 6.9 in the 
intermediate-risk group, the NNS in the high-risk group were 3.0, 1.8 and 1.7, 
respectively. No CRC was detected in the low-risk group and the NNS to detect 
an AN, or a SCL in this group rose to 37.0 and 18.9. The OR in the high-risk 
group for CRC detection was 17.5 (95% CI: 11.1-27.8) when compared with the 
intermediate-risk group.  
 
3. Validation of the Score  in the validation cohort 
In the ROC analysis, the FAST Score was more accurate for CRC 
detection in the validation cohort (AUC: 0.91, 95% CI: 0.90-0.93; p = 0.005) as 
shown in Figure 1.  This difference in the diagnostic accuracy was related to a 
statistically significant increase in specificity in the validation cohort as shown in 
Table 4. In contrast, there were no differences in sensitivity for CRC detection 
between the two cohorts. With respect to the calibration in the validation cohort, 
the Hosmer Lemeshow test significance was p=0.01. In addition, the diagnostic 
accuracy for AN (AUC: 0.79, 95% CI: 0.77-0.81; p = 0.05) and SCL (AUC: 0.78, 
95% CI: 0.76-0.80; p = 0.01) was reduced in the validation cohort. This 
reduction in overall accuracy was especially relevant in the Scottish studies: 
AUC for AN: 0.75 (95% 0.70-0.79; p = 0.002) and for SCL: 0.75 (95%0.71-0.79; 
p < 0.003). In contrast, the differences in the overall accuracy in the studies 
performed in Spain were statistically non-significant: AUC for AN: 0.81 (95% CI 
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0.78-0.83; p = 0.2) and for SCL: 0.79 (95% 0.77-0.81; p = 0.08).    Although the 
specificity for these two groups of colonic disease was also significantly 
increased in the validation cohort, the sensitivity was also reduced. These 
differences in sensitivity and specificity also occurred when comparing the data 
from the Scottish and Spanish studies (Supplementary Table 1).  
The FAST Score also discriminates the risk of CRC, AN and SCL 
detection in the validation cohort as shown in Table 3. In this regard,  851 
patients (21.4%) met high-risk group criteria with a 21.7% PPV for CRC 
detection; 2,378 (59.8%) met intermediate-risk group criteria with a 0.9% PPV 
and, finally, 747 (18.8%) patients met low-risk group criteria with a 0.0% PPV 
for CRC detection in the validation cohort. 
 
4. Diagnostic accuracy in the validation cohort according to the 
characteristics of the groups.  
In the post-hoc analysis, possible differences in the diagnostic accuracy 
of the FAST Score for CRC detection were assessed in the validation cohort 
according to several variables, as shown in Table 5. No significant differences 
in sensitivity for CRC detection were detected in any of the groups assessed. In 
addition, no differences were found in the diagnostic accuracy when comparing 
the patients referred for colonoscopy from primary care with those referred from 
secondary care. In contrast, the diagnostic accuracy, either overall or as 
specificity, was increased in the groups with a lower CRC prevalence. In this 
respect, differences were found in the CRC prevalence according to sex (male: 
7.1%, female: 3.6%, p < 0.001), age (<50 years: 1.3%, ≥50 years: 6.1%; p < 
0.001) and country (Spain: 6.5%, Scotland: 3.0%, p<0.001). In contrast, the 
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CRC prevalence was similar in both healthcare levels referring patients 
(primary: 5.6%, secondary: 4.9%, p = 0.4). Finally, the diagnostic accuracy was 
compared between the most commonly used analytical system (OC-Sensor) 
and the other analytical methods used, including the widely used HM-JACKarc, 
and between the validation cohort of the COLONPREDICT study and the rest of 
the study groups. As shown in Table 5, diagnostic accuracy was equal or higher 
with respect to the validation cohort, both for the analytical system and the 
study groups.   
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DISCUSSION 
 
1. Statement of principal findings 
Because f-Hb is dependent on age and sex,27 we developed and 
assessed the diagnostic accuracy of an easy to calculate prediction tool based 
not only on f-Hb, as originally suggested by Chen et al,28 but also age and 
sex.20 This prediction tool, termed the FAST Score, is highly accurate for CRC 
detection in symptomatic patients and allows establishment of three risk groups: 
CRC can be ruled out in those in the lowest risk group. In addition, we have 
confirmed that the threshold Scores we have examined are equally sensitive for 
CRC irrespective of, country, CRC prevalence, age, sex, healthcare level and 
analytical system used to estimate f-Hb.  In contrast, this prediction tool was 
less accurate for AN and SCL detection in the validation cohort.  
 
2. Strengths and weaknesses of the study 
We had the opportunity to access the individual data of the patients included 
in five of the six studies that have evaluated different analytical systems for the 
measurement of f-Hb  in symptomatic patients referred for colonoscopy.16–21 
These studies have evaluated the application of FIT in a wide variety of clinical 
settings with  differences in the strategy for invitation to the study, the analytical 
systems, the referral criteria to colonoscopy and the epidemiological 
characteristics of the cohorts included (age, sex and CRC, AN and SCL 
prevalence).. On the basis of these data, we have developed and externally 
validated a multivariable prediction tool according to the TRIPOD guidelines.24 A 
CRC prediction model, COLONPREDICT, had been previously developed and 
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validated.23 This prediction model was compared with the NICE referral 
guidelines used at that time3 demonstrating that a prediction model using f-Hb 
and other variables was more accurate than symptom-based referral criteria.23 
In the case of the FAST Score, its greatest advantage is simplicity and it could 
be calculated automatically by laboratory information management systems 
(LIMS) widely used to report results in laboratory medicine, with or without 
appropriate interpretative comments added by the LIMS, or through simple 
calculators developed for the Internet or as easy to download apps, since age 
and sex are generally available in health care systems and, if not, are easily 
collected from patients with symptoms prior to referral for colonoscopy along 
with the f-Hb. We think the simplicity of this prediction model may encourage 
the implementation of the FAST Score in comparison with previous developed 
prediction models for CRC detection that are based on several clinical and 
analytical variables which must be collected from disparate sources before the 
model is applied,12-15 
The FAST Score allows the rapid allocation of a patient to one of three risk 
groups: a high risk group where 90% of CRC are detected and these might be 
referred on an urgent basis, an intermediate risk group where 9% additional 
CRC are detected and such patients might be assessed further before referral, 
and a low risk group where, hypothetically, the remaining 1% would be found. 
This low risk group, with a negligible PPV accounts for nearly 19% of the 
validation cohort and these patients would probably not benefit from 
colonoscopy or possibly any further examination. In contrast, the NICE referral 
criteria for suspected CRC have a 68.2% sensitivity and a 50.2% specificity for 
CRC detection, and, in reality, these criteria cannot rule out CRC.23 
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The main weakness of our study is that the patients included in these 
studies had been selected a priori by health care professionals for further 
endoscopic evaluation. In consequence, we believe that the diagnostic 
accuracy of the FAST Score that we have developed, should be externally 
evaluated in a population with gastrointestinal symptoms attending primary care 
before its use is widely adopted. In fact, our findings strongly suggest that the 
FAST Score diagnostic accuracy will increase in populations in which CRC is at 
a low prevalence since this will result in an increase in specificity. We also 
propose that our f-Hb, age and sex based prediction tool should be compared 
within a randomised controlled trial with the currently available referral 
guidelines, such as the recent recommendations from NICE11 in terms of 
sensitivity, efficiency (endoscopy referrals to detect a CRC, delays) and, finally, 
effect on CRC survival.29 Additionally, we have found significant differences in 
the calibration of the model in the validation cohort, probably related to the 
differences in the CRC prevalence between the derivation (13.7%) and the 
validation cohort (5.2%).  These differences do not reduce the value of our 
findings. The prediction model is not aimed at estimating the individual risk but, 
rather, to determine different diagnostic strategies in symptomatic patients. 
However, the FAST Score will require not only validation in  primary healthcare 
but also recalibration in this setting before using it to provide risk-adjusted 
outcomes.   
Another limitation is the reduced diagnostic accuracy for detection of 
additional SCL. In part, this might be related to the different definitions used in 
the studies for AN and SCL in Spain and in Scotland. On the other hand, 
although this reduced accuracy could be considered as a limitation, there are 
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several arguments to support use of the FAST Score in this broader clinical 
perspective. Firstly, there are very few data published on AN detection models 
and tools,12,20 but there is no model or tool published to date for SCL detection, 
apart from the more complex COLONPREDICT score. As is widely recognised, 
there are criteria for the appropriateness of colonoscopy referral. These criteria 
have been evaluated in a prospective fashion showing that their diagnostic 
accuracy for both CRC and SCL detection is limited. As one example, a meta-
analysis has shown that the diagnostic OR of the American Society for 
Gastrointestinal Endoscopy and European Panel on the Appropriateness of 
Gastrointestinal Endoscopy (EPAGE)  criteria for relevant findings was 2.5 
(95% CI: 1.2-5.6),30 inferior to the OR of the FAST Score in both derivation and 
the validation cohorts. Further, although we cannot exclude relevant findings in 
the low risk group (PPV: 5.2-5.3%), the PPV in the inappropriate colonoscopy 
group according to the EPAGE II criteria ranges between 9.5 and 24.5%.31,32  
Finally, it is quite clear that the main endpoint of endoscopic evaluation of 
symptomatic patients must be the detection, or perhaps more importantly, the 
exclusion of those clinical conditions that threaten or significantly affect the 
quality of life, especially on account of the limited endoscopic resources 
available in many countries.  
 
3. Strengths and weaknesses in relation to other studies, discussing 
important differences in results 
The FAST Score was derived from the data from the same cohort as the 
COLONPREDICT score but, as commented previously, we had the opportunity 
to validate it in a wider geographical cohort. Both scores are tools based mainly 
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on f-Hb. In the case of the FAST score, we applied f-Hb in four categories, one 
of them 0 µg Hb/g faeces. Previous studies have shown the probability of ruling 
out CRC in patients with low f-Hb (<10 µg Hb/g faeces)20,25 or f-Hb of 0 µg Hb/g 
faeces.17 However, although this was not the case in our study, patients with 
this f-Hb had a 0.5, 0.06 and 0.015-fold risk when compared with those patients 
with 0-20, 20-200 and ≥200 µg Hb/ g faeces, respectively. 
In comparison with the COLONPREDICT score, the FAST Score has lower 
diagnostic accuracy. The COLONPREDICT score detects 90 and 99% CRC in 
30.9% and 60.5% of the derivation cohort, in contrast with the FAST Score, that 
requires 37.1% and 88.0% of the cohort to achieve these levels. However, 
these data should be further evaluated in real routine practice. Unlike the FAST 
score, COLONPREDICT requires an anorectal examination, tests done on 
venous blood and a detailed history to be performed before its calculation. So, 
the increased accuracy of the COLONPREDICT score in a controlled setting 
may be limited in daily practice because of its complexity compared to the 
simplicity of the FAST score that only requires f-Hb, age and sex. That is why 
we think both approaches should be compared in a primary care setting in a 
future study.   
 
4. Meaning of the study: possible explanations and implications for 
clinicians and policymakers 
Even though we now need to evaluate the applicability of the FAST Score in 
a routine primary care setting, the implications for clinicians and policymakers 
are quite clear. Prediction tools based on f-Hb measured by high quality 
automated quantitative FIT should be the cornerstone of the evaluation of the 
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symptomatic patient and used as the criterion to determine the appropriateness 
of the referrals for colonoscopy. We consider that the FAST Score does provide 
an objective tool to guide who requires further investigation in secondary care. 
In fact, recently published (2015) NICE referral guidelines for suspected cancer 
have included the use of tests for the presence of occult blood in faeces in 
symptomatic patients with a PPV for CRC detection below 3%.11 However, we 
think that f-Hb-based prediction tools could be a better basis for the evaluation 
of all symptomatic patients.  
Furthermore, we believe strategies for prompt diagnosis of patients with 
suspected CRC should be designed based on sensitivity rather than on the 
PPV. As an example, if we use the 3% PPV threshold for CRC for further 
evaluation determined in the 2015 NICE guidelines,11 we would miss one out of 
ten CRC, since the PPV in the  FAST intermediate  risk group in the derivation 
and validation cohorts is 2.8% and 0.9%, respectively. Thus, we consider that 
prompt diagnosis strategies should determine a 90% sensitivity threshold for 
urgent referral and a 99% sensitivity referral threshold for colonoscopy 
evaluation. The secondary endpoint should be specificity as long as low 
specificity is associated with unnecessary referrals to colonoscopy, with its 
corresponding risks. In fact, the specificity of the FAST Score at the 90% 
sensitivity threshold seems acceptable when compared with other available 
clinical criteria, e.g., NICE referral criteria.18 In contrast, the specificity at the 
99% sensitivity threshold is extremely low. However, it must be emphasised 
that, at this threshold, to the Score rules out CRC. 
 
5. Unanswered questions and future research 
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Two main issues need to be answered in the future. As stated previously, 
the diagnostic accuracy and applicability of the FAST Score tool in a primary 
care setting must be addressed in a prospective study and, ideally, compared 
with the COLONPREDICT score and current age and symptom-based referral 
guidelines. Secondly, further prediction tools based on laboratory findings other 
than f-Hb should be designed and evaluated in a primary care setting. In this 
respect, the evaluation of newer CRC biomarkers in risk scoring models would 
be a necessary prerequisite to their introduction as investigations to assist the 
CRC diagnosis process in symptomatic patients.  
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Figure legends 
Figure 1:  
ROC curves for the FAST Score for colorectal cancer detection in derivation 
and validation cohorts. The AUC of the ROC curves are compared with the Chi-
square homogeneity area test. 
ROC: receiver operating characteristic, AUC: area under the curve, 95% CI: 
95% confidence interval. 
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Table 1: Characteristics of the different cohorts included in the study. 
Authors, date, country, reference Number 
 
 
Male 
sex 
Age in years 
(median and 
range) 
Colorectal 
cancer 
Advanced 
neoplasia 
Significant 
colorectal 
lesions 
Rectal 
bleeding 
Change 
in bowel 
habit 
Primary 
health care 
referral 
Analytical system for 
estimation of faecal 
haemoglobin concentration  
Derivation cohort 
Cubiella et al, 2016, Spain.23 1,572 51.5% 68 (20-96) 13.7% 26.7% 29.5% 59.5% 57.2% 22.9% OC-Sensor: 100% 
Validation cohorts 
McDonald et al, 2013, Scotland,17 280 40.4% 60 (15-89) 2.1% 12.1% 21.6% 25.7% 6.1% 100.0% OC-Sensor: 100% 
Mowat et al, 2015, Scotland,19 750 45.5% 64 (16-90) 3.7% 10.1% 14.7% 33.9% 42.7% 100.0% OC-Sensor: 100% 
Godber et al, 2016, Scotland,21 484 42.1% 63 (18-84) 2.3% 6.2% 9.3% 24.0% 27.5% 0.0% HM-JACKarc:100% 
Rodriguez-Alonso et al, 2015, 
Spain, 20 
1,003 46.9% 63 (18-90) 3.0% 13.3% 15.5% 34.2% 35.6% 17.2% OC-Sensor: 100% 
Cubiella et al, 2016, Spain,23  1,459 48.7% 64 (19-100) 9.0% 21.5% 29.2% 51.5% 52.7% 39.2% OC-Sensor: 49.7% 
OC-Auto 3 Latex: 13.8% 
FOB Gold: 2.4% 
Linear i-FOB: 34.1% 
Overall 3,976 46.2% 65 (15-100) 5.2% 14.8% 19.5% 38.6% 40.1% 
 
37.6% OC-Sensor: 69.3% 
OC-Auto 3 Latex: 5.1% 
FOB Gold: 0.9% 
Linear i-FOB: 12.5% 
HM-JACKarc:12.2% 
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Table 2: Diagnostic accuracy of the FAST Score at two threshold Scores with 
90% and 99% sensitivity for colorectal cancer (CRC), advanced neoplasia (AN) 
and significant colonic lesion (SCL) detection in the derivation cohort 
 FAST  Score ≥4.50 FAST Score ≥2.12 
CRC AN1 SCL2 CRC AN1 SCL2 
Number positive 37.1% 88.0% 
Sensitivity3 89.8% 
(84.7-93.3) 
75.4% 
(70.9-79.4) 
72.7% 
(68.4-76.7) 
100.0%  
(97.8-100.0) 
98.8% 
(97.1-99.6) 
97.8% 
(95.9-98.9) 
Specificity3 71.3% 
(68.8-73.7) 
76.9% 
(74.3-79.3) 
77.8% 
(75.2-80.2) 
13.9% 
(12.1-15.9) 
15.9% 
(13.9-18.2) 
16.1% 
(14.0-18.4) 
Positive predictive 
value3 
33.2% 
(29.4-37.2) 
54.4% 
(50.2-58.5) 
57.8% 
(53.7-61.9) 
15.6% 
(13.7-17.6) 
30.0% 
(27.6-32.5) 
32.8% 
(30.3-35.3) 
Negative predictive 
value3 
97.8% 
(96.6-98.6) 
89.6% 
(87.4-91.4) 
87.2% 
(84.9-89.2) 
100% 
(97.5-100.0) 
97.3% 
(93.5-99) 
94.7% 
(90.2-97.3) 
Positive likelihood 
ratio4 
3.13 
(2.84-3.44) 
3.27  
(2.90-3.68) 
3.28 
 (2.90-3.71) 
1.16  
(1.14-1.19) 
1.18  
(1.14-1.21) 
1.17 
(1.13-1.2) 
Negative likelihood 
ratio4 
0.14 
(0.10-0.21) 
0.32  
(0.27-0.38) 
0.35  
(0.30-0.41) 
NE 0.07  
(0.03-0.18) 
0.13  
(0.07-0.25) 
Diagnostic odds 
ratio4 
21.8  
(13.8-34.4) 
10.2  
(7.8-13.2) 
9.4  
(7.3-12.0) 
NE 15.7  
(6.4-38.4) 
8.7  
(4.5-16.5) 
1Advanced neoplasia = colorectal cancer plus advanced adenoma (see text) 
2Significant colonic lesion = colorectal cancer plus advanced adenoma (see 
text) plus other significant pathology (see text) 
3Values are expressed as percentages with 95% confidence intervals in 
parentheses.  
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4Values are expressed as absolute numbers and 95% confidence intervals in 
parentheses.  
NE: not evaluable. 
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Table 3: Diagnostic yield for colorectal cancer, advanced neoplasia and 
significant colonic lesion detection according to the FAST Score risk 
classification in the derivation cohort and validation cohort 
 Derivation cohort (1,572) Validation cohort (3,976) 
 Low1 Intermediate2 High3 Low1 Intermediate2 High3 
Number patients (%) 12 50.9 37.1 18.8 59.8 21.4 
Colorectal 
cancer  
PPV (%) 0 2.8 33.2 0 0.9 21.7 
NNS NE 35.7 3.0 NE 111.1 4.6 
OR (95% CI) 
NE6 17.5 (11.1-27.8) 7 NE6 29.4 (18.9-45.4) 7 
NE8 NE8 
Advanced 
neoplasia4 
PPV (%) 2.7 12.3 54.4 2.6 8.9 41.7 
NNS 37 8.1 1.8 38.5 11.2 2.4 
OR (95% CI) 
5.1 (2.1-12.7) 6 8.5 (6.5-11.1) 7 3.7 (2.3-6) 6 7.3 (6.1-9) 7 
43.6 (17.7-107) 8 27.4 (17-44) 8 
Significant 
colonic lesion5 
PPV (%) 5.3 14.5 57.8 5.6 11.9 52.6 
NNS 18.9 6.9 1.7 17.8 8.4 1.9 
OR (95% CI) 
3.0 (1.5-6.0) 6 8.1 (6.2-10.4) 7 2.2 (1.6-3.2) 6 8.2 (6.8-9.8) 7 
24.4 (12.6-47.1) 8 18.5 (13.2-26) 8 
1Low-risk cohort: FAST Score <2.12. 
2Intermediate-risk cohort: FAST Score ≥2.12 and <4.50. 
3High-risk cohort: FAST Score ≥4.50. 
4Advanced neoplasia = colorectal cancer plus advanced adenoma (see text)  
5Significant colonic lesion = colorectal cancer plus advanced adenoma plus 
other significant pathology (see text) 
6OR and 95% CI when the intermediate risk compared with the low-risk group 
7OR and 95% CI when the high risk compared with the intermediate-risk group. 
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8OR and 95% CI when the high risk compared with the low-risk group. 
 
PPV: positive predictive value, NE: non-evaluable, NNS: number needed to 
scope; OR, odds ratio; 95% CI, 95% confidence interval. 
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Table 4: Sensitivity and specificity for colorectal cancer (CRC), advanced 
neoplasia (AN) and significant colonic lesion (SCL) of the FAST Score at the 
thresholds (4.50 and 2.12) with 90% and 99% sensitivity for CRC detection in 
the derivation and validation cohorts  
FAST Score 
FAST Score ≥4.50 FAST Score ≥2.12 
Sensitivity1 Specificity1 Sensitivity1 Specificity1 
CRC 
Derivation 89.8%  (84.7-93.3) 71.3% (68.8-73.7) 100.0%  (97.8-100) 13.9% (12.1-15.9) 
Validation 89.3% (84.1-93.0) 82.3% (81.1-83.5) 100.0% (97.7-100) 19.8% (18.6-21.1) 
Significance4 1 <0.001 NE <0.001 
AN2 
Derivation 75.4% (70.9-79.4) 76.9% (74.3-79.3) 98.8% (97.1-99.6) 15.9% (13.9-18.2) 
Validation 60.7% (56.6-64.7) 85.4% (84.1-86.5) 96.7% (94.9-98) 21.5% (20.1-22.9) 
Significance4 <0.001 <0.001 0.03 <0.001 
SCL3 
Derivation 72.7% (68.4-76.7) 77.8% (75.2-80.2) 97.8% (95.9-98.9) 16.1% (14.0-18.4) 
Validation 57.8% (54.3-61.3) 87.4% (86.2-88.5) 94.5% (92.6-96) 22.0% (20.6-23.5) 
Significance4 <0.001 <0.001 0.005 <0.001 
1Values are expressed as percentages with 95% confidence intervals in 
parentheses.  
2Advanced neoplasia = colorectal cancer plus advanced adenoma (see text)  
3Significant colonic lesion = colorectal cancer plus advanced adenoma (see 
text) plus other significant pathology (see text) 
4Significance of the sensitivity and specificity differences between both cohorts 
in the Chi-square test. Differences with p<0.05 are considered statistically 
significant. 
NE: non-evaluable.
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Table 5: Diagnostic accuracy for colorectal cancer detection of the FAST Score in the validation cohort according to the 
characteristics of the cohorts and the patients included: AUC and sensitivity and specificity at the Score thresholds (4.50 and 2.12) 
with 90% and 99% sensitivity for CRC detection. 
 
FAST score FAST Score ≥4.50 FAST Score ≥2.12 
AUC (95% CI) p1 Sensitivity p2 Specificity p2 Specificity p2 
Healthcare 
setting 
Primary (1,496) 0.90 (0.87-0.93) 
0.2 
89.2% 
1 
81.8% 
0.5 
21.2% 
0.1 
Secondary (2,480) 0.92 (0.91-0.94) 89.3% 82.6% 19.0% 
Region 
Spain (2,462) 0.90 (0.89-0.92) 
0.6 
86.7% 
0.5 
85.4% 
<0.001 
18.3% 
0.004 
Scotland (1,514) 0.92 (0.88-0.95) 89.3% 82.3% 22.2% 
Age 
<50 years (761) 0.93 (0.90-0.96) 
0.07 
80.0% 
0.3 
90.6% 
<0.001 
56.0% 
<0.001 
≥50 years (3,215) 0.91 (0.88-0.92) 89.8% 80.3% 10.8% 
Sex 
Male (1,838) 0.89 (0.86-0.91) 
0.01 
90.0% 
0.8 
77.6% 
<0.001 
8.0% 
<0.001 
Female (2,138) 0.93 (0.91-0.95) 88.2% 86.3% 29.6% 
Colorectal cancer 
prevalence 
<5% (2,517) 0.92 (0.90-0.95) 
0.03 
88.0% 
0.6 
86.3% 
<0.001 
23.4% 
<0.001 
≥5% (1,459) 0.88 (0.86-0.91) 90.1% 75.0% 13.2% 
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FIT3 
OC-Sensor (2,758) 0.92 (0.91-0.94) 90.1% 83.1% 23.7% 
OC-Auto 3 Latex (202) 
 
0.88 (0.81-0.94) 0.1 95.2% 0.7 56.4% <0.001 7.2% <0.001 
FOB Gold reagents (35) 0.88 (0.63-1.00) 0.7 100% 1 72.7% 0.1 24.2% 1 
Linear i-FOB (497) 0.89 (0.84-0.93) 0.1 82.9% 0.2 86.4% 0.08 8.4% <0.001 
HM-JACKarc (484) 0.97 (0.94-1.00) 0.02 90.9% 1 84.6% 0.4 14.0% <0.001 
Study4 
Cubiella et al 2016 (1,459) 0.88 (0.86-0.91) 90.1% 75% 13.2% 
Godber et al 2015 (484) 0.97 (0.94-1.00) <0.001 90.9% 1 84.6% <0.001 14.0% 0.7 
Mowat et al 2015 (750) 0.89 (0.83-0.94) 0.9 82.1% 0.3 85.5% <0.001 26.3% <0.001 
McDonald et al 2013 (280) 0.95 (0.92-0.99) <0.001 100% 1 86.9% <0.001 25.5% <0.001 
Rodriguez-Alonso et al 2015 
(1,003) 
0.93 (0.91-0.95) 0.003 90.0% 1 87.6% <0.001 25.2% <0.001 
1Significance of the area under the curve differences between cohorts with the Chi-square homogeneity test. Differences with 
p<0.05 are considered statistically significant. 
2Significance of the sensitivity and specificity differences between cohorts with the Chi-square test. Differences with p<0.05 are 
considered statistically significant. 
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3The cohorts are compared with the OC-Sensor cohort. 
4The cohorts are compared with the Cubiella et al study cohort. 
AUC, area under the curve; CI, confidence interval; FIT, faecal immunochemical test for haemoglobin
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Supplementary table 1:  Comparison of the diagnostic accuracy of the FAST 
Score for advanced neoplasia and significant colonic lesions in the Spanish and 
Scottish validation studies. Comparison with the derivation cohort. 
Lesion Thresholds of the 
FAST Score 
Derivation Scotland Spain 
Value p4 Value p4 
A
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
1
 Sensitivity3 
4.50 
75.4% 
(70.9-79.4) 
50.7% 
(42.2-59.2) 
<0.001 
63.9% 
(59.2-68.3) 
<0.001 
2.12 
98.8% 
(97.1-99.6) 
95.0% 
(89.6-97.8) 
0.01 
97.3% 
(95.2-98.5) 
0.1 
Specificity3 
4.50 
76.9% 
(74.3-79.3) 
86.8% 
(84.8-88.5) 
<0.001 
84.4% 
(82.8-86.0) 
<0.001 
2.12 
15.9% 
(13.9-18.2) 
23.2% 
(21.0-25.6) 
<0.001 
20.3% 
(18.6-22.1) 
0.03 
S
ig
n
if
ic
a
n
t 
c
o
lo
n
ic
 l
e
s
io
n
2
 
Sensitivity3 
4.50 
72.7% 
(68.4-76.7) 
50.4% 
(43.7-57.1) 
<0.001 
60.9% 
(56.6-65.0) 
<0.001 
2.12 
97.8% 
(95.9-98.9) 
91.5% 
(86.9-94.7) 
<0.001 
95.8% 
(93.7-97.3) 
0.07 
Specificity3 
4.50 
77.8% 
(75.2-80.2) 
89.1% 
(87.3-90.8) 
<0.001 
86.2% 
(84.6-87.7) 
<0.001 
2.12 
16.1% 
(14-18.4) 
23.8% 
(21.5-26.2) 
<0.001 
20.8% 
(19.0-22.7) 
0.001 
 
1Advanced neoplasia = colorectal cancer plus advanced adenoma (see text)  
2Significant colonic lesion = colorectal cancer plus advanced adenoma (see 
text) plus other significant pathology (see text)  
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3Values are expressed as percentages with 95% confidence intervals in 
parentheses.  
4Significance of the sensitivity and specificity differences between derivation 
cohort and the Scottish and Spanish studies included in the validation cohort 
with the Chi-square test. Differences with p<0.05 are considered statistically 
significant. 
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Supplementary note: Investigators of the COLONPREDICT study 
Complexo Hospitalario Universitario de Ourense: Joaquín Cubiella, Pablo Vega, 
María Salve, Marta Díaz-Ondina, Irene Blanco, Pedro Macía, Eloy Sánchez, 
Javier Fernández-Seara. 
Hospital Universitario de Canarias: Enrique Quintero, Natalia González-López 
Complejo Hospitalario de Pontevedra: Victoria Álvarez Sánchez, José Mera, 
Juan Turnes. 
Hospital Universitari Mútua de Terrassa: Fernando Fernández-Bañares, Victoria 
Gonzalo, Mar Pujals. 
Registre del Càncer de Catalunya Pla Director d'Oncologia de Catalunya, 
Hospital Duran i Reynals, L’Hospitalet de Llobregat: Josepa Ribes, Ramón 
Cleries, Xavier Sanz. 
Consorci Sanitari de Terrassa: Jaume Boadas, Sara Galter, Rebeca Gimeno, 
Eva Garcia-Lanuza 
Corporació Sanitària i Universitària Parc Taulí: Rafel Campo, Marta Pujol,  Eva 
Martínez-Bauer. 
Departamento de Bioquímica, CATLAB, Viladecavalls, Barcelona: Antonio 
Alsius. 
Donostia Hospital: Luis Bujanda, Jesús Bañales, María J Perugorria. 
Hospital de Sagunto: Joan Clofent, Ana Garayoa. 
Hospital Clínico Universitario de Zaragoza: Ángel Ferrández, Marina Solano 
Sánchez. 
Hospital Dr. Josep Trueta: Leyanira Torrealba, Virginia Piñol. 
Hospital Universitario de Móstoles: Daniel Rodriguez-Alcalde, Jorge López-
Vicente. 
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